BillionToOne, Inc. Class A (BLLN) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of BillionToOne, Inc. Class A stock $13.77, price $114, upside -87.9%, quality 59 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Fair value 30%+ above price?No
Quality 50+?Yes
In an uptrend?Unknown
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 29, 2026.
How to read this chart
12‑month range $64.03 – $149.97 · fair‑value band $12.08 – $15.96 · the $114.00 price screens above the $13.77 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 29, 2026.
Follow BillionToOne, Inc. Class A Common Stock in your weekly email
Every Wednesday you see whether BillionToOne, Inc. Class A Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection.
Show moreShow less
It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision.
BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.
Stock analysis
BillionToOne, Inc. Class A (BLLN) currently trades at $114.00, while our model-based Fair Value estimate is $13.77, 87.9% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $19.02 per share, and 0 of the 24 models we run sit above the $114.00 price.
Bear case: the Earnings-Based group reads lowest at $6.12, and 24 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: $12.08 (bear) to $15.96 (bull), the price of $114.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
BillionToOne, Inc. Class A Common Stock reported revenue of $305M in FY2025 versus $71.7M in FY2023, a compound +106.2%/yr. Reported net income was $7.5M in FY2025.
Key figures
Market cap $6.2B Mid · P/E ratio 166.1 · P/S ratio 4.06 · EPS (TTM) $0.6300 · Net margin 2.4% · Return on equity 10.7% · Return on assets (EBIT) −16.4% · Operating margin 5.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).
What moves the price
The share trades about 24% below its 52-week high and 78% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at −88%, BLLN screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely ($2.97 to $50.60). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear$12.08Fair Value $13.77Bull$15.96
Price $114.00 · Upside -87.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.5213 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV$13.30$13.76$14.1674
FCF DCF$16.03$19.05$28.3972
Growth DCF$15.68$20.38$27.9071
All 24 models by family
DCF Models
FCF DCF$16.03$19.05$28.3972
Owner Earnings$10.59$10.95$11.6670
5Y Revenue Exit$14.64$17.67$24.0066
5Y EBITDA Exit$16.99$22.42$33.0767
5Y P/E Exit$14.07$17.99$23.2064
10Y Revenue Exit$14.98$20.20$23.4161
10Y EBITDA Exit$16.78$25.09$39.6860
10Y P/E Exit$14.72$19.02$25.7758
Earnings-Based
Graham-Dodd$1.19$8.29$11.6356
Lynch FV$4.28$6.12$7.9554
PEG = 1.0$4.28$6.12$7.9551
EPV$13.30$13.76$14.1674
Multiples
P/E Multiple$2.88$3.85$4.8163
P/S Multiple$2.23$2.97$3.7158
P/B Multiple$37.95$50.60$63.2555
EV/EBIT$13.87$15.46$17.0666
EV/EBITDA$15.95$18.25$20.5467
EV/Revenue$12.50$13.96$15.4354
Asset-Based
NCAV (Graham)$6.31$9.57$11.9654
Growth DCF
Growth DCF$15.68$20.38$27.9071
Rev-Margin DCF$15.08$18.73$26.3865
Economic Profit
Residual Income$7.64$7.10$6.9163
ROIC Compounder$14.21$16.20$18.7764
Growth Earnings
Growth-Adj P/E$5.68$8.12$10.5660
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
not computed
Growth Forecast
A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+70.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+26.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +66.3% a year for the price and +23.7% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (72 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: The business draws strength from fast-growing oncology liquid biopsies backed by positive tissue-free study data, yet it shows no durable moat and continues to post low returns on equity and assets.
Main risk: Continued heavy dependence on the prenatal testing franchise exposes revenue to reimbursement risk that would directly constrain cash flow and limit oncology expansion.
BillionToOne relies heavily on prenatal testing for revenue while oncology liquid biopsies grow fast from a smaller base. Its recent peer-reviewed study shows the tissue-free Northstar Response tracks treatment response on par with or better than tumor-informed assays, without needing tissue samples. Does the simplified workflow drive faster oncology adoption or does reimbursement risk keep the focus on the prenatal franchise?
Compare BillionToOne, Inc. Class A Common Stock with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 121 stocks
Beats the industry median on 4/12 measures
Overall it trails its industry peers.
Valuation
Quality Score59 · Above median
Fair Value upside−87.9% · Bottom 25%
Profitability
Return on equity (12 months)10.7% · Above median
Return on assets1.2% · Below median
Net margin (12 months)8.4% · Above median
Operating margin (12 months)5.0% · Below median
Growth and dividend
Revenue growth (quarter YoY)64.4% · Top 25%
Balance sheet
Debt / equity0.12× · Above median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (12 months)166.1× · Priciest 25%
P/B12.93× · Priciest 25%
P/S (12 months)15.62× · Priciest 25%
Price / free cash flow395.1× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 40
PAST (return on equity)43· sector 14
HEALTH (low debt)94· sector 95
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "BillionToOne, Inc. Class A Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/BLLN
Frequently asked questions
Is BillionToOne, Inc. Class A (BLLN) overvalued or undervalued?
As of Oct 29, 2026, our model estimates a fair value of $13.77 versus a price of $114.00, about −88% upside (overvalued).
What is the fair value of BLLN?
Our model-based fair value for BillionToOne, Inc. Class A Common Stock is $13.77 (as of Oct 29, 2026), built from audited fundamentals. The current price: $114.00.
What is the quality score of BLLN?
BillionToOne, Inc. Class A Common Stock has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BillionToOne, Inc. Class A (BLLN)?
Our model-based price target is the fair value of $13.77 (as of Oct 29, 2026) from 24 valuation models. Cautious scenario $12.08, optimistic scenario $15.96. It is a calculation from audited fundamentals, not an analyst target.
What is the BillionToOne, Inc. Class A Common Stock stock forecast for 2026?
Our models put fair value at $13.77, about −88% upside versus a price of $114.00 (overvalued). Cautious scenario $12.08, optimistic scenario $15.96. The calculation is refreshed regularly with new filings.
What is the revenue of BillionToOne, Inc. Class A (BLLN)?
BillionToOne, Inc. Class A Common Stock reported trailing-twelve-month revenue of about $397M (latest available figure, as of Oct 29, 2026).
What growth is priced into BillionToOne, Inc. Class A (BLLN)?
For today's price to be fair in a discounted-cash-flow model, BillionToOne, Inc. Class A Common Stock would have to grow free cash flow by +70.3 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 2 years revenue grew +106.2 % per year. As of Oct 29, 2026.
What discount rate (WACC) does the fair value of BLLN use?
Our models discount BillionToOne, Inc. Class A Common Stock at 9.7 %: a base by market capitalisation (mid), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BillionToOne, Inc. Class A Common Stock that is +70.3 % per year a year over ten years, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has BillionToOne, Inc. Class A (BLLN) delivered so far?
Over the past 2 years revenue at BillionToOne, Inc. Class A Common Stock grew +106.2 % a year. The price currently implies +70.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BillionToOne, Inc. Class A (BLLN) growing?
The median revenue growth in the sector is +6.1 % a year. That is the yardstick for the growth priced into BillionToOne, Inc. Class A Common Stock (+70.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BillionToOne, Inc. Class A (BLLN)?
The free-cash-flow yield on the price is 0.25 %: that much free cash flow BillionToOne, Inc. Class A Common Stock produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BillionToOne, Inc. Class A (BLLN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BillionToOne, Inc. Class A Common Stock it is $13.77 per share (as of Oct 29, 2026), against a price of $114.00. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is BillionToOne, Inc. Class A Common Stock stock overvalued or undervalued in 2026?
As of Oct 29, 2026, BLLN trades above its calculated fair value: price $114.00, fair value $13.77, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BLLN?
No. The price is what the market pays today ($114.00); the fair value is what the company's own numbers justify ($13.77). For BillionToOne, Inc. Class A Common Stock the two are $100.23 per share apart. That gap is exactly why we show both numbers side by side.
How much is BillionToOne, Inc. Class A Common Stock worth?
The market values BillionToOne, Inc. Class A Common Stock at about $6.2B (market capitalisation, as of Oct 29, 2026). Per share that is $114.00; our models calculate a fair value of $13.77 per share.
What do the bullish and bearish scenarios say about BLLN?
Our models span a range for BillionToOne, Inc. Class A Common Stock: cautious scenario $12.08, base $13.77, optimistic $15.96 per share (as of Oct 29, 2026, price $114.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BLLN?
BillionToOne, Inc. Class A Common Stock trades at a price-to-earnings ratio of 166.1 (as of Oct 29, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $13.77 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 218.2 (reported for FY2025: 700.7). Other multiples: P/B 12.9, P/S 15.6.
How solid is the balance sheet of BillionToOne, Inc. Class A (BLLN)?
Balance-sheet figures for BillionToOne, Inc. Class A Common Stock (as of Oct 29, 2026): return on equity 10.7%, debt of 0.12 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is BLLN from its 52-week high?
BillionToOne, Inc. Class A Common Stock trades at $114.00, about 24% below its 52-week high of $149.97 and 78% above the low of $64.03 (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of $13.77 is for.
Which stocks are comparable to BillionToOne, Inc. Class A Common Stock?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BillionToOne, Inc. Class A Common Stock stock attractive at the current price?
The data as of Oct 29, 2026: price $114.00, calculated fair value $13.77 (−88%), Quality Score 59/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BLLN calculated?
We run BillionToOne, Inc. Class A Common Stock through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $13.77, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. BillionToOne, Inc. Class A Common Stock itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BillionToOne, Inc. Class A (BLLN)?
The closing price on Oct 28, 2026 was $114.00. Our model-based fair value is $13.77, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BillionToOne, Inc. Class A Common Stock right now?
The price sits above even our optimistic bull case ($15.96). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of BillionToOne, Inc. Class A Common Stock
How large is the market capitalisation of BillionToOne, Inc. Class A (BLLN)?
The market capitalisation of BillionToOne, Inc. Class A Common Stock is $6.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BillionToOne, Inc. Class A (BLLN)?
The price-to-sales ratio of BillionToOne, Inc. Class A Common Stock is 4.06 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BillionToOne, Inc. Class A (BLLN)?
Earnings per share at BillionToOne, Inc. Class A Common Stock are $0.6300 (price ÷ EPS = P/E 166.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BillionToOne, Inc. Class A (BLLN)?
The net margin of BillionToOne, Inc. Class A Common Stock is 2.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BillionToOne, Inc. Class A (BLLN)?
The return on equity (ROE) of BillionToOne, Inc. Class A Common Stock is 10.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BillionToOne, Inc. Class A (BLLN)?
On an EBIT basis the return on assets of BillionToOne, Inc. Class A Common Stock is −16.4% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BillionToOne, Inc. Class A (BLLN)?
The operating margin of BillionToOne, Inc. Class A Common Stock is 5.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BillionToOne, Inc. Class A (BLLN)?
Revenue at BillionToOne, Inc. Class A Common Stock is growing +64.4% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does BillionToOne, Inc. Class A (BLLN) hold?
BillionToOne, Inc. Class A Common Stock holds more cash than debt, $387M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch BillionToOne, Inc. Class A Common Stock in the live analysis
One click puts BillionToOne, Inc. Class A Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 29, 2026